PREFER
Mats G. Hansson, PREFER co-ordinator

Mats G. Hansson, coordinator

Mats G. Hansson is Professor of Biomedical Ethics and Director of the Centre for Research Ethics & Bioethics (CRB) at Uppsala University. The Centre is a multi-disciplinary unit awarded for international excellence with long experience of managing large international projects. Mats Hansson received his first degree in Biology in 1974 and then moved into Theology, Philosophy, and Bioethics. He has led several multidisciplinary projects in bioethics, has published extensively in this area, and has ongoing collaborations in several European countries, partly associated with leading ethical, legal, and social issues work packages of eight EU-projects.
 

Conny Berlin, Project leader PREFER

Conny Berlin, Project leader

Conny Berlin is Global Head of Quantitative Safety and Epidemiology at Novartis Pharma AG. Her responsibilities include promoting a quantitative safety and epidemiology culture which enables evaluation, understanding and communication of safety data and benefit-risk to support decision-making at all stages of the drug life-cycle. Conny Berlin holds a degree in mathematics from the University of Rostock, Germany. Since joining Novartis in 2007, she has led several initiatives to improve signal detection, safety and benefit-risk evaluation. She is a member of the company’s Medical Safety Review Board and of the Benefit-Risk Steering Committee.

Isabelle Huys, deputy co-ordinator and academic leader WP 4

Isabelle Huys, deputy coordinator and public lead for recommendations

Isabelle Huys has a PhD in pharmaceutical sciences from KU Leuven (Belgium) and an LLM in IPR and regulatory sciences from the Max-Planck-Institute (Munich, Germany). Since 2010, she is a full-time professor in regulatory sciences at the Faculty of Pharmaceutical Sciences and a member of the Center for IT & Intellectual Property IT law (CiTiP) of KU Leuven. Isabelle Huys has been Advisor for European Projects, Intellectual Property Officer and Regional Development officer at the KU Leuven R&D department. She did post-doctoral research at the Law Faculty of KU Leuven on patents and biomedical inventions. Isabelle Huys is deputy co-ordinator of PREFER and also academic leader for the work package on recommendations.

Rebecca Noel, deputy project leader

Rebecca Noel, deputy project leader

Rebecca (Becky) Noel is currently the Global Leader for Benefit-Risk Assessment at Eli Lilly and Company.  Since joining Lilly in 2002, Becky has been extensively involved in leading the development of systematic approaches to benefit-risk assessment, both internally at Lilly and externally via the PhRMA Benefit-Risk Action Team (BRAT), the IMI PROTECT WP, CIRS’s Task Force on Benefit-Risk Assessment, the ICH, and via multiple other forums such as the Institute of Medicine and DIA. 

Sheila Dickinson, Novartis

Sheila Dickinson, assistant project leader

Sheila Dickinson, MSc in Medical Statistics, has led a team supporting implementation of a structured benefit-risk approach in Novartis Pharma, in particular for submissions. This has included work on templates and training for use by teams using a structured benefit-risk approach, and also development and delivery of broad training on benefit-risk for a more general audience within the company. She has also worked directly with a project team to support their use of structured benefit-risk for a submission. She has worked in the pharmaceutical industry for over 20 years.

Susan Bhatti, Industry leader WP1

Susan Bhatti, private management lead

Dr Susan Bhatti (Merck KGaA) has worked in Regulatory Affairs in various roles for over 20 years and joined Global Regulatory Affairs at Merck in 2013. She has many years’ experience of clinical trials as well as project management and now works closely with representatives of pharmaceutical associations in her role as Director EU Global Regulatory and Scientific Policy. Susan Bhatti is resoponsible for PREFER key performance indicators.

Carl Steinbeisser, Project Manager

Carl Steinbeißer, public co-lead and project manager

Carl Steinbeißer (Steinbeißer Project Management) has done project management of EC funded project for 6 years and is specialised on IMI projects. He consulted and managed large life science projects such as Cancer-ID (IMI), OncoTrack (IMI),  ENS@T-Cancer (FP7) and ESGI (FP7). He holds an MA in European Ethnology and History and has also worked as a product manager for a publishing company. Carl Steinbeßer is responsible for operational project management in PREFER.

Monika Brand, Industry co-lead WP 1

Monika Brand, private management co-lead

Monika Brand (Actelion Pharmaceuticals) has worked for more than 20 years in the industry and build up extensive experience in design, conduct, reporting of epidemiology/observational studies including Post Authorisation Safety Studies in response to regulatory needs. Monika Brand is leading the data management work in PREFER.

PREFER communications team

The PREFER communications team consists of representatives from public and private partners. The work is led by a communications manager from Uppsala University, with task co-leads from Lilly. Communications to patient groups are led by ECPC. Communication activities for the HTA community are led by KCE. The private partners are also represented by Novartis.

Kristin Bullock, Communications

Kristin Bullok, Communications

Kristin E. Bullok, PhD, is part of the communications group within PREFER.  She has 10 years of experience in the pharmaceutical industry at Eli Lilly and Company, based in Indianapolis, Indiana in the US.  She currently is a consultant on the science of benefit and risk assessment, which has allowed participation in strategy development and benefit-risk patient preference research. Her previous roles within scientific communications, both within and outside of the pharmaceutical industry, provided in-depth experience creating communications to regulatory agencies, as well as to the public and scientific community. 

Isabelle Manneh-Vangramberen, ECPC

Isabelle Manneh-Vangramberen, ECPC

Isabelle Manneh-Vangramberen leads patient input on PREFER management and communications and recommendations. She also provides input on methodology and . She is ECPC's Projects Coordinator and executive body for all EU funded projects. Isabelle Manneh-Vangramberen holds a Bachelor of Science in Pharmacy & Pharmaceutical Sciences, a Master degree in Public Health from Florida International University, in addition to, a post-Master in European Studies specialising in EU Policy & Project Management from the Catholic University of Louvain. Her professional experience ranges from community-based participatory research aiming at prevention in the area of Public Health, Global and Environmental Health, to EU Policy, Project Management and the provision of Humanitarian Aid in conflict and post-conflict settings under the United Nations, among many others covering the US, Europe, Middle East and Asia.

Gudrun Briat, KCE communications

Gudrun Briat, HTA communications coordinator

Gudrun Briat is responsible for the communication of Belgian Health Care Knowledge Centre (KCE) reports through the organisation’s website, press contacts, social media, etc. She is also involved in making the syntheses of KCE’s scientific reports accessible for a larger public. Gudrun participated in the activities of the work package on “dissemination” of the Joint Action 2 of EunetHTA. Her activities in that work package were related to setting up a Community of Practice for dissemination of study results. Gudrun Briat is involved in the PREFER communication for the dissemination of study results to the HTA community.

Rebecca Nyquist, communications team member

Rebecca Nyquist, Communications

Rebecca Nyquist is a Senior Expert Medical Writer at Novartis Pharma AG. She holds an MS in Chemistry from UCLA and a PhD in Biophysics from the University of Illinois Champaign-Urbana. Since joining Novartis in 2009, she has served as lead writer on global regulatory submission documents and health authority interactions. In recent years she has been involved in integrating structured benefit-risk methodology into clinical submission documents at Novartis. She has a passion for the challenges associated with communication within cross-functional teams.

Irina Cleemput, Academic co-leader WP 4

Irina Cleemput, public co-lead for recommendations

Irina Cleemput is senior health economist at the Belgian Health Care Knowledge Centre (KCE) since 2004.   Through KCE, she has been involved in EUnetHTA from the very beginning of the network. Currently, KCE is co-leading the work package on “Quality management, methodological guidance and tools”. In PREFER, Irina is coordinating the HTA and Payers Stakeholder Advisory Group and co-leading work package 4 on recommendations. Irina will also participate in the other work packages of PREFER.

Gudrun Briat, KCE communications

Gudrun Briat, HTA communications coordinator

Gudrun Briat is responsible for the communication of Belgian Health Care Knowledge Centre (KCE) reports through the organisation’s website, press contacts, social media, etc. She is also involved in making the syntheses of KCE’s scientific reports accessible for a larger public. Gudrun participated in the activities of the work package on “dissemination” of the Joint Action 2 of EunetHTA. Her activities in that work package were related to setting up a Community of Practice for dissemination of study results. Gudrun Briat is involved in the PREFER communication for the dissemination of study results to the HTA community.

Isabelle Manneh-Vangramberen, ECPC

Isabelle Manneh-Vangramberen, ECPC

Isabelle Manneh-Vangramberen leads patient input on PREFER management and communications and recommendations. She also provides input on methodology and . She is ECPC's Projects Coordinator and executive body for all EU funded projects. Isabelle Manneh-Vangramberen holds a Bachelor of Science in Pharmacy & Pharmaceutical Sciences, a Master degree in Public Health from Florida International University, in addition to, a post-Master in European Studies specialising in EU Policy & Project Management from the Catholic University of Louvain. Her professional experience ranges from community-based participatory research aiming at prevention in the area of Public Health, Global and Environmental Health, to EU Policy, Project Management and the provision of Humanitarian Aid in conflict and post-conflict settings under the United Nations, among many others covering the US, Europe, Middle East and Asia.

Lydia Makaroff, ECPC

Lydia Makaroff, ECPC

Lydia Makaroff (ECPC), provides input to PREFER management. She is ECPC’s Director. She has ten years' international experience in non-communicable disease research and policy development in academia, the pharmaceutical industry, and the non-profit sector. She conducted scientific research during her PhD at the Australian National University and as a senior post-doctoral fellow at the University of Washington Medical Center with support from the Australian Cancer Research Foundation and the Cancer Council. After working in Global Market Access at a pharmaceutical company, she joined the International Diabetes Federation as their Epidemiology and Public Health Manager. Her team quantified the global impact of diabetes and published research on prevalence, cost, and complications. She monitored national governments' commitments to non-communicable diseases, provided advocacy tools to national associations, and wrote policy papers on strategies to improve access to medicines and reduce health inequalities.

Antonio Ciaglia, IAPO contact person, PREFER patient advisory group

Antonio Ciaglia, IAPO

Antonio Ciaglia (IAPO) leads patient input to PREFER's  methodology work and also gives input to the project management. He carries out research activities and contributes toward the development of the IMI-GetReal Research Project. He brings formal qualitative and quantitative research expertise and has quickly developed knowledge and skills in health research and the drug/device development pathway. Before joining IAPO, Antonio undertook an AW Mellon Foundation-funded postdoctoral fellowship at the University of the Witwatersrand, Johannesburg, where he developed a research project in the field of comparative media policy and political communication. He also worked as a Policy and Research Intern at the Leicestershire-based Building and Social Housing Foundation, where he developed a research project on issues regarding high-rise housing policy in Britain and Europe. Antonio holds a PhD in Political Science from the Scuola Normale Superiore of Florence, an MA in Political Communication and a BA in Communication Studies from the University of Perugia.

Valentina Strammielloas, EPF

Valentina Strammielloas, EPF

Valentina Strammielloas (EPF) is part of the PREFER patient stakeholder advisory group.

Jenny Sharpe, MDUK

Jenny Sharpe, MDUK

Jenny Sharpe (MDUK) leads the patient input in the clinical case studies. She also gives input to PREFER communications, methodology and recommendations. Jenny is MDUK’s Research Communications Officer and is primarily responsible for translating research findings into a language that patients can understand. This involves engaging with a range of people, including scientists, industry representatives, clinicians, and individuals and families affected by neuromuscular conditions. Prior to joining MDUK, she completed a PhD in mitochondrial biology at University College London.